We proved that GD-NAIs can exert an inhibitory effect on CML by regulating multiple signaling pathways, including PD-L1 expression and the PD-1 checkpoint pathway in cancer, the PI3K/AKT, JAK/STAT, TGF-β, estrogen, Notch and Wnt signaling pathways. This evidence concerns the gene SOAT1 and chronic myelogenous leukemia, BCR-ABL1 positive.